ArticleFrontiers in pharmacology2022

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.

Bo Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.